SCHEMBL24508253

SCHEMBL24508253

CC(=O)CNCCCCOCCCCC(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 1/20 0.34
CES2 O00748 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
PLA2G2C Q5R387 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ADRB2 P07550 1/20 0.32
ADRB3 P13945 1/20 0.32
PAOX Q6QHF9 3/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KDM4C Q9H3R0 2/20 0.31
KDM4A O75164 1/20 0.31
PHF8 Q9UPP1 1/20 0.31
KDM2A Q9Y2K7 1/20 0.31
EPHX2 P34913 2/20 0.31
PLA2G2A P14555 1/20 0.31
KISS1R Q969F8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21106781 0.85 RARB (0.33) RARBMAOAMAOBMEN1KMT2A
SCHEMBL6917720 0.82 KDM4C (0.43) RARBPLA2G2CKDM4EALDH1A1SMN1; SMN2
SCHEMBL23560305 0.81 CES2 (0.53) CES2PLA2G2CMEN1KMT2APAOX
SCHEMBL24511296 0.80 LMNA (0.37) RARBALDH1A1
SCHEMBL21106927 0.79 KDM4E (0.52) RARBPLA2G2CMEN1KMT2APAOX
SCHEMBL23560491 0.77 CYP2C19 (0.44) MEN1KMT2AALDH1A1
SCHEMBL21106926 0.77 HRH4 (0.36) MEN1KMT2AADRB2ADRB3SMN1; SMN2
SCHEMBL21106551 0.77 KDM4E (0.53) PLA2G2CMEN1KMT2APAOXKDM4E
SCHEMBL13815320 0.76 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2KISS1R
SCHEMBL20801013 0.75 TP53 (0.46) MAOAMAOBPAOXALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4328219-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) 2024-02-28 EP disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 US disclosed
US-20230190940-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-06-22 US disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 WO disclosed
WO-2022125790-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 RARB 2259/4885CES2 1669/4885MAOA 2771/4885
US-20230190940-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 RARB 2259/4885CES2 1669/4885MAOA 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.